Clinical Trials

Inclusion Criteria:

•  Age ≥ 18 years.
• Histological confirmation of indolent B-cell lymphoma that can include any of the following:
  • Follicular lymphoma (grade 1 or 2 or 3A);
  •  Marginal zone lymphoma (Nodal or extranodal).
•  Any stage disease.
• Initial or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression.
• ECOG Performance Status (PS) ≤ 4 (Appendix I).
• Negative pregnancy test done ≤7 days prior to registration, for persons of childbearing potential only.
• Provide written informed consent.
• Ability to complete questionnaire(s) by themselves or with assistance.
• Willingness to provide optional tissue specimens for correlative research (see Section 17.0). If required at Registration (ALL sample types require this statement, if bone marrow, urine, etc., are mandatory, include similar statement).
• Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study). Virtual visits can also be considered as an option for applicable items.

Exclusion Criteria: 

• Any of the following:
  • Pregnant women;
  • Nursing women;
  • Men or women of childbearing potential who are unwilling to employ adequate contraception.
• T-cell lymphoma.
• Small and chronic lymphocytic lymphoma.
• Grade 3B follicular lymphoma.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/3/23. Questions regarding updates should be directed to the study team contact.